wiegveld schreef op 21 augustus 2020 08:05:
Op een farma website staat t al.
Abbvie heeft 1 jaar extra tijd en dat komt ze goed uit.
www.fiercepharma.com/pharma/gilead-s-...As of June, Rinvoq had secured 15% of "in-play" market share in RA patients, CEO Rick Gonzalez told analysts on a July earning call, and the med could soon overtake megablockbuster Humira in terms of prescriptions for first-time users.
While Rinvoq posted $149 million in second-quarter sales, that figure topped the Street consensus of $110 million and put the drug on track to hit $600 million by year's end.
And those sales are just in RA. AbbVie is pushing the drug through late-stage clinical trials in both eczema and ankylosing spondylitis, hoping it can snare as many indications as possible to pick up slack from Humira, which faces U.S. biosimilars beginning in 2023.
Krijg die mensen er nog maar eens af!